Fortress Biotech Inc (NASDAQ:FBIO) has been given a consensus recommendation of “Hold” by the six brokerages that are currently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $11.00.

Several equities analysts have commented on the company. Zacks Investment Research raised Fortress Biotech from a “sell” rating to a “hold” rating in a research report on Tuesday, October 10th. ValuEngine lowered Fortress Biotech from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Finally, HC Wainwright set a $11.00 price objective on Fortress Biotech and gave the company a “buy” rating in a research report on Tuesday, January 2nd.

In other news, SVP George Avgerinos sold 12,000 shares of the firm’s stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $3.55, for a total transaction of $42,600.00. Following the completion of the transaction, the senior vice president now directly owns 352,495 shares in the company, valued at $1,251,357.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Lindsay A. Md Rosenwald purchased 40,000 shares of Fortress Biotech stock in a transaction dated Monday, November 6th. The shares were bought at an average price of $25.00 per share, with a total value of $1,000,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 40,000 shares of the company’s stock, valued at $1,000,000. The disclosure for this purchase can be found here. 33.30% of the stock is owned by company insiders.

Several large investors have recently modified their holdings of FBIO. Citadel Advisors LLC bought a new position in shares of Fortress Biotech during the third quarter valued at $101,000. National Asset Management Inc. increased its holdings in shares of Fortress Biotech by 38.4% during the second quarter. National Asset Management Inc. now owns 28,850 shares of the biopharmaceutical company’s stock valued at $138,000 after acquiring an additional 8,000 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of Fortress Biotech by 2.8% during the second quarter. Rhumbline Advisers now owns 38,846 shares of the biopharmaceutical company’s stock valued at $185,000 after acquiring an additional 1,075 shares in the last quarter. Parametric Portfolio Associates LLC increased its holdings in shares of Fortress Biotech by 3.3% during the second quarter. Parametric Portfolio Associates LLC now owns 59,224 shares of the biopharmaceutical company’s stock valued at $281,000 after acquiring an additional 1,913 shares in the last quarter. Finally, Wells Fargo & Company MN increased its holdings in shares of Fortress Biotech by 365.4% during the third quarter. Wells Fargo & Company MN now owns 119,736 shares of the biopharmaceutical company’s stock valued at $529,000 after acquiring an additional 94,008 shares in the last quarter. Hedge funds and other institutional investors own 12.09% of the company’s stock.

Shares of Fortress Biotech (FBIO) traded down $0.18 during trading on Friday, reaching $3.78. The company’s stock had a trading volume of 228,485 shares, compared to its average volume of 120,108. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.69 and a quick ratio of 2.69. The stock has a market capitalization of $189.96, a price-to-earnings ratio of -2.06 and a beta of 1.11. Fortress Biotech has a fifty-two week low of $2.38 and a fifty-two week high of $5.13.

Fortress Biotech (NASDAQ:FBIO) last announced its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.24). The firm had revenue of $46.89 million for the quarter, compared to analysts’ expectations of $50.75 million. Fortress Biotech had a negative net margin of 65.80% and a negative return on equity of 61.43%. Fortress Biotech’s quarterly revenue was up 4709.2% compared to the same quarter last year. equities analysts expect that Fortress Biotech will post -1.99 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Fortress Biotech Inc (FBIO) Receives $11.00 Average PT from Brokerages” was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.dailypolitical.com/2018/02/01/fortress-biotech-inc-fbio-receives-11-00-average-pt-from-brokerages.html.

Fortress Biotech Company Profile

Fortress Biotech, Inc, formerly Coronado Biosciences, Inc, is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products.

Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.